Bold Therapeutics is a clinical-stage biopharma company based in Vancouver, British Columbia founded in 2018 to develop and commercialize BOLD-100, a first-in-class small molecule therapeutic with applications in both oncology (cancer) and infectious disease (COVID-19).

BOLD-100 has a unique multimodal pro-apoptotic mechanism-of-action (MoA). In oncology, BOLD-100 (1) alters the unfolded protein response (UPR) through selective GRP78 inhibition; and (2) induces reactive oxygen species (ROS) which causes DNA damage and cell cycle arrest. Collectively, these effects result in cell death (apoptosis) in both sensitive and resistant cancers. As an antiviral, BOLD-100 interferes with viral replication – and has been shown to be effective at low micromolar concentrations. Importantly, the results from our nonclinical and clinical work to date suggest that BOLD-100 is selective for cancer and virus-infected cells, accomplishing these goals with minimal toxicity.

Based on compelling preclinical and early clinical results, Bold Therapeutics is focusing its clinical development efforts on some of the most challenging indications where existing therapies are largely ineffective, resulting in a significant unmet medical need.